Measuring adherence to antiretroviral treatment in resource-poor settings: The feasibility of collecting routine data for key indicators

BMC Health Services Research

Volumn 10, Issue , 2010, Pages

  Chalker, John C ^a   Andualem, Tenaw ^b   Gitau, Lillian N ^c   Ntaganira, Joseph ^d   Obua, Celestino ^e   Tadeg, Hailu ^b   Waako, Paul ^e   Ross Degnan, Dennis ^f  

^a Center for Pharmaceutical Management   (United States)

^b Management Sciences for Health   (Ethiopia)

^c Management Sciences for Health   (Kenya)

^d UNIVERSITY OF RWANDA   (Rwanda)

^e MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AFRICA; AGED; ARTICLE; EVALUATION; FEASIBILITY STUDY; FEMALE; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; INTERVIEW; MALE; MEDICAL RECORD; METHODOLOGY; MIDDLE AGED; PATIENT COMPLIANCE; REPRODUCIBILITY; RETROSPECTIVE STUDY; STANDARD; STATISTICS; UTILIZATION REVIEW;

ADULT; AFRICA, EASTERN; AGED; ANTI-RETROVIRAL AGENTS; DATA COLLECTION; FEASIBILITY STUDIES; FEMALE; HEALTH FACILITIES; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MALE; MEDICAL RECORDS; MIDDLE AGED; PATIENT COMPLIANCE; QUALITY INDICATORS, HEALTH CARE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 77649292846     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-10-43     Document Type: Article

References (31)

1. Antiretroviral therapy adherence and viral suppression in HIV-infected. JH Arnsten PA Demas H Farzadegan RW Grant MN Gourevitch CJ Chang D Buono H Eckholdt AA Howard EE Schoenbaum, Clin Infect Dis 2001 33 1417 1423 10.1086/323201 11550118
2. Adherence and HIV drug resistance. AK Sethi, HIV Clin Trials 2004 5 112 115 10.1310/N53E-1930-NJMW-GL7C 15116287
3. Adherence to protease inhibitor therapy and outcomes in patients with. DL Paterson S Swindells J Mohr M Brester EN Vergis C Squier M Wagener N Singh, Ann Intern Med 2000 133 21 30 10877736
4. Less than 95% adherence to nonnucleoside reverse transcriptase inhibitor therapy can lead to viral suppression. D Bangsberg, Clinical Infectious Diseases 2006 43 939 941 10.1086/507526 16941380
5. Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges? R Smith, Proc Biol Sci 2006 273 617 624 10.1098/rspb.2005.3352 16537134
6. Variations in patients' adherence to medical recommendations. MR DiMatteo, Med Care 2004 42 200 209 10.1097/01.mlr.0000114908.90348.f9 15076819
7. Adherence to medication. L Osterberg T Blaschke, N Engl J Med 2005 353 487 497 10.1056/NEJMra050100 16079372
8. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. L Ferradini A Jeannin L Pinoges J Izopet D Odhiambo L Mankhambo G Karungi Szumilin S Balandine G Fedida M Carrieri B Spire N Ford JM Tassie P Guerin C Brasher, Lancet 2006 367 1335 1342 10.1016/S0140-6736(06)68580-2 16631912
9. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. PT Nieuwkerk FJ Oort, J Acquir Immune Defic Syndr 2005 38 445 448 10.1097/01.qai.0000147522.34369.12 15764962
10. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. K Wools-Kaloustian S Kimaiyo L Diero A Siika J Sidle CT Yiannoutsos B Musick R Einterz KH Fife W Tierney, AIDS 2006 20 41 48 10.1097/01.aids.0000196177.65551.ea 16327318
11. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. A Ammassari MP Trotta R Murri F Castelli P Narciso P Noto J Vecchiet A D'ArminioMontforte AW Wu A Antinori, J Acquir Immune Defic Syndr 2002 31 Suppl 3 123 S127 12562034
12. A comparison study of multiple measures of adherence to HIV protease inhibitors. H Liu CE Golin LG Miller RD Hays CK Beck S Sanandaji J Christian T Maldonado AH Kaplan NS Wenger, Ann Intern Med 2001 134 968 977 11352698
13. Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy. GP Bisson R Gross S Bellamy J Chittams M Hislop L Regensberg I Frank G Maartens J Nachega, PLoS Medicine 2008 5 109 10.1371/journal.pmed.0050109 18494555
14. th 2009.
15. The assessment of refill compliance using pharmacy records: methods. JF Steiner AV Prochazka, J Clin Epidemiol 1997 50 105 116 10.1016/S0895-4356(96) 00268-5 9048695
16. Adherence to antiretroviral therapy in patients receiving free treatment from a government hospital in Blantyre, Malawi. DJ Bell Y Kapitao R Sikwese JJ van Oosterhout DG Lalloo, J Acquir Immune Defic Syndr 2007 45 560 563 10.1097/QAI.0b013e3180decadb 17558333
17. Assessment of adherence to antiviral therapy in HIV-infected children. J Farley S Hines A Musk S Ferrus V Tepper, J Acquir Immune Defic Syndr 2003 33 211 218 10.1097/00126334-200306010-00016 12794557
18. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. PW Hugen N Langebeek DM Burger B Zomer R van Leusen R Schuurman P Koopmans Y Hekster, J Acquir Immune Defic Syndr 2002 30 324 334 12131570
19. Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana. R Vriesendorp A Cohen P Kristanto B Vrijens P Rakesh B Anand H Iwebor J Stiekema, Eur J Clin Pharmacol 2007 63 1115 1121 10.1007/s00228-007-0369-2 17882408
20. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. LG Miller RD Hays, AIDS Read 2000 10 177 185 10758022
21. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. JH Oyugi J Byakika-Tusiime ED Charlebois C Kityo R Mugerwa P Mugyenyi D Bangsberg, J Acquir Immune Defic Syndr 2004 36 1100 1102 10.1097/00126334- 200408150-00014 15247564
22. Adherence to antiretroviral therapies: state of the science. NR Reynolds, Curr HIV Res 2004 2 207 214 10.2174/1570162043351309 15279584
23. World Health Organization: Patient monitoring guidelines for HIV care and antiretroviral therapy (ART). WHO, Geneva; WHO 2006
24. Report on the global HIV/AIDS epidemic. UNAIDS, Geneva: UNAIDS 2008
25. Measuring adherence to antiretroviral treatment in resource-poor settings: The clinical validity of key indicators. D Ross-Degnan M Pierre-Jacques F Zhang H Tadeg L Gitau J Ntaginara R Balikuddembe J Chalker A Wagner, BMC Health Services Research 2010 10 42 10.1186/1472-6963-10-42 20170478
26. Monitoring Adherence and Defaulting for Antiretroviral Therapy in Five East African Countries: An Urgent Need for Standards. J Chalker T Andualem O Minzi J Ntaganira A Ojoo P Waako D Ross-Degnan, JIAPAC 2008 7 193 199 18626124
27. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. JJ van Oosterhout N Bodasing JJ Kumwenda C Nyirenda J Mallewa PR Cleary MP de Baar R Schuurman DM Burger E Zijlstra, Trop Med Int Health 2005 10 464 470 10.1111/j.1365-3156.2005.01409.x 15860093
28. Antiretroviral adherence interventions: a review of current literature and ongoing studies. JM Simoni PA Frick DW Pantalone BJ Turner, Top HIV Med 2003 11 185 198 14724327
29. Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. CK Fairley A Permana TR Read, HIV Med 2005 6 366 369 10.1111/j.1468-1293.2005.00322.x 16156886
30. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. R Grossberg Y Zhang R Gross, J Clin Epidemiol 2004 57 1107 1110 10.1016/j.jclinepi.2004.04.002 15528063
31. Individual and system level factors associated with treatment non adherence. G van Servellen B Chang L Garcia E Lombardi, AIDS Patient Care STDS 2002 16 269 281 10.1089/10872910260066705 12133262